Medicamen Biotech Limited (MEDICAMEQ) - Net Assets
Based on the latest financial reports, Medicamen Biotech Limited (MEDICAMEQ) has net assets worth Rs2.76 Billion INR (≈ $29.80 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs3.72 Billion ≈ $40.23 Million USD) and total liabilities (Rs964.38 Million ≈ $10.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MEDICAMEQ PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs2.76 Billion |
| % of Total Assets | 74.07% |
| Annual Growth Rate | 18.95% |
| 5-Year Change | 88.13% |
| 10-Year Change | 928.91% |
| Growth Volatility | 38.89 |
Medicamen Biotech Limited - Net Assets Trend (2006–2026)
This chart illustrates how Medicamen Biotech Limited's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Medicamen Biotech Limited.
Annual Net Assets for Medicamen Biotech Limited (2006–2026)
The table below shows the annual net assets of Medicamen Biotech Limited from 2006 to 2026. Also explore how fast is Medicamen Biotech Limited growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs2.76 Billion ≈ $29.80 Million |
+29.50% |
| 2025-03-31 | Rs2.13 Billion ≈ $23.01 Million |
+2.80% |
| 2024-03-31 | Rs2.07 Billion ≈ $22.38 Million |
+7.02% |
| 2023-03-31 | Rs1.93 Billion ≈ $20.92 Million |
+32.05% |
| 2022-03-31 | Rs1.46 Billion ≈ $15.84 Million |
+10.22% |
| 2021-03-31 | Rs1.33 Billion ≈ $14.37 Million |
+9.63% |
| 2020-03-31 | Rs1.21 Billion ≈ $13.11 Million |
+39.92% |
| 2019-03-31 | Rs866.34 Million ≈ $9.37 Million |
+16.12% |
| 2018-03-31 | Rs746.08 Million ≈ $8.07 Million |
+178.59% |
| 2017-03-31 | Rs267.81 Million ≈ $2.90 Million |
+49.54% |
| 2016-03-31 | Rs179.09 Million ≈ $1.94 Million |
+4.21% |
| 2015-03-31 | Rs171.85 Million ≈ $1.86 Million |
+3.91% |
| 2014-03-31 | Rs165.38 Million ≈ $1.79 Million |
+5.22% |
| 2013-03-31 | Rs157.17 Million ≈ $1.70 Million |
-21.81% |
| 2012-03-31 | Rs201.01 Million ≈ $2.17 Million |
-1.52% |
| 2011-03-31 | Rs204.12 Million ≈ $2.21 Million |
+25.53% |
| 2010-03-31 | Rs162.61 Million ≈ $1.76 Million |
+25.47% |
| 2009-03-31 | Rs129.60 Million ≈ $1.40 Million |
+11.89% |
| 2008-03-31 | Rs115.83 Million ≈ $1.25 Million |
+14.99% |
| 2007-03-31 | Rs100.73 Million ≈ $1.09 Million |
+17.58% |
| 2006-03-31 | Rs85.67 Million ≈ $926.49K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Medicamen Biotech Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs135.63 Million | 4.92% |
| Other Components | Rs2.62 Billion | 95.08% |
| Total Equity | Rs2.76 Billion | 100.00% |
Medicamen Biotech Limited Competitors by Market Cap
The table below lists competitors of Medicamen Biotech Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HLV LIMITED
NSE:HLVLTD
|
$48.13 Million |
|
Wästbygg Gruppen AB (publ)
ST:WBGR-B
|
$48.13 Million |
|
Elinoil Hellenic Petroleum Company S.A
AT:ELIN
|
$48.14 Million |
|
Agile Content SA
MC:AGIL
|
$48.14 Million |
|
Lesico Ltd
TA:LSCO
|
$48.12 Million |
|
Ckd Bio
KO:063160
|
$48.11 Million |
|
Promateris SA
RO:PPL
|
$48.10 Million |
|
W S Industries (I) Limited
NSE:WSI
|
$48.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medicamen Biotech Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 2,127,809,000 to 2,755,500,000, a change of 627,691,000 (29.5%).
- Net income of 96,413,000 contributed positively to equity growth.
- Dividend payments of 13,563,000 reduced retained earnings.
- New share issuances of 535,679,000 increased equity.
- Other comprehensive income decreased equity by 17,190,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs96.41 Million | +3.5% |
| Dividends Paid | Rs13.56 Million | -0.49% |
| Share Issuances | Rs535.68 Million | +19.44% |
| Other Comprehensive Income | Rs-17.19 Million | -0.62% |
| Other Changes | Rs26.35 Million | +0.96% |
| Total Change | Rs- | 29.50% |
Book Value vs Market Value Analysis
This analysis compares Medicamen Biotech Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.59x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 29.57x to 1.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | Rs11.09 | Rs328.05 | x |
| 2007-03-31 | Rs13.04 | Rs328.05 | x |
| 2008-03-31 | Rs15.04 | Rs328.05 | x |
| 2009-03-31 | Rs16.78 | Rs328.05 | x |
| 2010-03-31 | Rs21.06 | Rs328.05 | x |
| 2011-03-31 | Rs26.42 | Rs328.05 | x |
| 2012-03-31 | Rs25.45 | Rs328.05 | x |
| 2013-03-31 | Rs18.77 | Rs328.05 | x |
| 2014-03-31 | Rs19.48 | Rs328.05 | x |
| 2015-03-31 | Rs19.03 | Rs328.05 | x |
| 2016-03-31 | Rs18.06 | Rs328.05 | x |
| 2017-03-31 | Rs25.69 | Rs328.05 | x |
| 2018-03-31 | Rs66.62 | Rs328.05 | x |
| 2019-03-31 | Rs74.06 | Rs328.05 | x |
| 2020-03-31 | Rs99.22 | Rs328.05 | x |
| 2021-03-31 | Rs108.78 | Rs328.05 | x |
| 2022-03-31 | Rs119.89 | Rs328.05 | x |
| 2023-03-31 | Rs155.28 | Rs328.05 | x |
| 2024-03-31 | Rs163.50 | Rs328.05 | x |
| 2025-03-31 | Rs167.49 | Rs328.05 | x |
| 2026-03-31 | Rs206.34 | Rs328.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medicamen Biotech Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.88%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.35x
- Recent ROE (3.50%) is below the historical average (7.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 17.44% | 2.87% | 1.54x | 3.95x | Rs6.38 Million |
| 2007 | 14.95% | 2.51% | 1.29x | 4.61x | Rs4.99 Million |
| 2008 | 13.04% | 1.96% | 1.49x | 4.47x | Rs3.52 Million |
| 2009 | 10.63% | 1.60% | 1.88x | 3.53x | Rs812.51K |
| 2010 | 24.45% | 3.91% | 1.76x | 3.55x | Rs23.50 Million |
| 2011 | 13.60% | 2.26% | 1.76x | 3.43x | Rs7.36 Million |
| 2012 | -4.10% | -0.82% | 1.46x | 3.43x | Rs-28.35 Million |
| 2013 | -31.35% | -7.70% | 0.98x | 4.15x | Rs-64.99 Million |
| 2014 | 0.57% | 0.13% | 1.13x | 3.90x | Rs-15.60 Million |
| 2015 | 2.56% | 0.57% | 1.13x | 4.00x | Rs-12.78 Million |
| 2016 | 2.69% | 0.71% | 1.12x | 3.35x | Rs-13.10 Million |
| 2017 | 19.27% | 6.26% | 1.12x | 2.74x | Rs24.82 Million |
| 2018 | 13.55% | 9.07% | 0.95x | 1.58x | Rs26.52 Million |
| 2019 | 13.88% | 9.81% | 0.90x | 1.58x | Rs33.62 Million |
| 2020 | 10.96% | 10.59% | 0.69x | 1.50x | Rs11.70 Million |
| 2021 | 9.13% | 10.76% | 0.58x | 1.46x | Rs-11.60 Million |
| 2022 | 10.17% | 12.90% | 0.51x | 1.54x | Rs2.51 Million |
| 2023 | 7.67% | 10.54% | 0.51x | 1.44x | Rs-44.97 Million |
| 2024 | 5.28% | 6.10% | 0.61x | 1.42x | Rs-97.67 Million |
| 2025 | 3.34% | 4.37% | 0.55x | 1.40x | Rs-141.70 Million |
| 2026 | 3.50% | 4.88% | 0.53x | 1.35x | Rs-179.14 Million |
Industry Comparison
This section compares Medicamen Biotech Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $55,732,551,119
- Average return on equity (ROE) among peers: 12.78%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medicamen Biotech Limited (MEDICAMEQ) | Rs2.76 Billion | 17.44% | 0.35x | $48.12 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $354.09 Million | 3.07% | 2.25x | $31.32 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.00 Billion | 13.75% | 2.66x | $426.21 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $2.31 Million | -8.08% | 0.08x | $804.25 Million |
| Abbott India Limited (ABBOTINDIA) | $36.99 Billion | 32.48% | 0.40x | $6.27 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $29.96 Billion | 21.83% | 0.26x | $4.81 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $33.31 Billion | 7.66% | 0.64x | $1.30 Billion |
| Alkem Laboratories Limited (ALKEM) | $75.58 Billion | 20.97% | 0.52x | $7.07 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.29 Billion | 15.52% | 0.29x | $154.33 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $52.38 Billion | 9.95% | 0.36x | $1.80 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $326.47 Billion | 10.68% | 0.52x | $10.79 Billion |
About Medicamen Biotech Limited
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-… Read more